Pharma Bribes

Boston-based Alexion Pharmaceuticals will pay <strong><a href="https://www.courthousenews.com/wp-content/uploads/2020/07/SEC.pdf">$21.5 million</a></strong> to settle charges of bribing officials in Turkey and Russia to get favorable treatment for its primary drug, Soliris, which treats a blood disease, the SEC said Thursday.</p>

WASHINGTON — Boston-based Alexion Pharmaceuticals agreed Thursday to pay $21.5 million to settle SEC charges of bribing officials in Turkey and Russia to get favorable treatment for its primary drug, Soliris, which treats a blood disease.

Categories / Business, International, Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.